These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Treatment of recurrent glioblastoma multiforme with GliaSite brachytherapy. Chan TA; Weingart JD; Parisi M; Hughes MA; Olivi A; Borzillary S; Alahakone D; Detorie NA; Wharam MD; Kleinberg L Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1133-9. PubMed ID: 15990019 [TBL] [Abstract][Full Text] [Related]
3. The role of dose escalation with intracavitary brachytherapy in the treatment of localized CNS malignancies: outcomes and toxicities of a prospective study. Wernicke AG; Sherr DL; Schwartz TH; Pannullo SC; Stieg PE; Boockvar JA; Moliterno JA; Ivanidze J; Trichter S; Sabbas AM; Parashar B; Nori D Brachytherapy; 2010; 9(1):91-9. PubMed ID: 19850535 [TBL] [Abstract][Full Text] [Related]
4. Preclinical evaluation of a novel device for delivering brachytherapy to the margins of resected brain tumor cavities. Stubbs JB; Frankel RH; Schultz K; Crocker I; Dillehay D; Olson JJ J Neurosurg; 2002 Feb; 96(2):335-43. PubMed ID: 11838809 [TBL] [Abstract][Full Text] [Related]
5. GliaSite brachytherapy for treatment of recurrent malignant gliomas: a retrospective multi-institutional analysis. Gabayan AJ; Green SB; Sanan A; Jenrette J; Schultz C; Papagikos M; Tatter SP; Patel A; Amin P; Lustig R; Bastin KT; Watson G; Burri S; Stea B Neurosurgery; 2006 Apr; 58(4):701-9; discussion 701-9. PubMed ID: 16575334 [TBL] [Abstract][Full Text] [Related]
6. Results of a phase II trial of the GliaSite radiation therapy system for the treatment of newly diagnosed, resected single brain metastases. Rogers LR; Rock JP; Sills AK; Vogelbaum MA; Suh JH; Ellis TL; Stieber VW; Asher AL; Fraser RW; Billingsley JS; Lewis P; Schellingerhout D; Shaw EG; J Neurosurg; 2006 Sep; 105(3):375-84. PubMed ID: 16961129 [TBL] [Abstract][Full Text] [Related]
7. Feasibility and safety of GliaSite brachytherapy in treatment of CNS tumors following neurosurgical resection. Wernicke AG; Sherr DL; Schwartz TH; Pannullo SC; Stieg PE; Boockvar JA; Ivanidze J; Moliterno JA; Parashar B; Trichter S; Sabbas AM; Nori D J Cancer Res Ther; 2010; 6(1):65-74. PubMed ID: 20479550 [TBL] [Abstract][Full Text] [Related]
8. Biodistribution and dosimetry of an aqueous solution containing sodium 3-(125I)iodo-4-hydroxybenzenesulfonate (Iotrex) for brachytherapy of resected malignant brain tumors. Stubbs JB; Strickland AD; Frank RK; Simón J; McMillan K; Williams JA Cancer Biother Radiopharm; 2000 Dec; 15(6):645-56. PubMed ID: 11190496 [TBL] [Abstract][Full Text] [Related]
9. Treatment of recurrent high-grade gliomas with GliaSite brachytherapy: a prospective mono-institutional Italian experience. Gobitti C; Borsatti E; Arcicasa M; Roncadin M; Franchin G; Minatel E; Skrap M; Zanotti B; Tuniz F; Cimitan M; Capra E; Drigo A; Trovò MG Tumori; 2011; 97(5):614-9. PubMed ID: 22158493 [TBL] [Abstract][Full Text] [Related]
10. Radiation safety considerations in GliaSite 125I brain implant procedures. Strzelczyk J; Safadi R Health Phys; 2004 May; 86(5 Suppl):S120-3. PubMed ID: 15069303 [TBL] [Abstract][Full Text] [Related]
11. Feasibility and safety of outpatient brachytherapy in 37 patients with brain tumors using the GliaSite Radiation Therapy System. Chino K; Silvain D; Grace A; Stubbs J; Stea B Med Phys; 2008 Jul; 35(7):3383-8. PubMed ID: 18697562 [TBL] [Abstract][Full Text] [Related]
12. Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma. Mamelak AN; Rosenfeld S; Bucholz R; Raubitschek A; Nabors LB; Fiveash JB; Shen S; Khazaeli MB; Colcher D; Liu A; Osman M; Guthrie B; Schade-Bijur S; Hablitz DM; Alvarez VL; Gonda MA J Clin Oncol; 2006 Aug; 24(22):3644-50. PubMed ID: 16877732 [TBL] [Abstract][Full Text] [Related]
13. Imaging after GliaSite brachytherapy: prognostic MRI indicators of disease control and recurrence. Kleinberg L; Yoon G; Weingart JD; Parisi M; Olivi A; Detorie NA; Chan TA Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1385-91. PubMed ID: 19394153 [TBL] [Abstract][Full Text] [Related]
14. Recurrent malignant gliomas: survival following interstitial brachytherapy with high-activity iodine-125 sources. Gutin PH; Leibel SA; Wara WM; Choucair A; Levin VA; Philips TL; Silver P; Da Silva V; Edwards MS; Davis RL J Neurosurg; 1987 Dec; 67(6):864-73. PubMed ID: 3316532 [TBL] [Abstract][Full Text] [Related]
15. Experimental validation of dose calculation algorithms for the GliaSite RTS, a novel 125I liquid-filled balloon brachytherapy applicator. Monroe JI; Dempsey JF; Dorton JA; Mutic S; Stubbs JB; Markman J; Williamson JF Med Phys; 2001 Jan; 28(1):73-85. PubMed ID: 11213925 [TBL] [Abstract][Full Text] [Related]
16. GliaSite brachytherapy boost as part of initial treatment of glioblastoma multiforme: a retrospective multi-institutional pilot study. Welsh J; Sanan A; Gabayan AJ; Green SB; Lustig R; Burri S; Kwong E; Stea B Int J Radiat Oncol Biol Phys; 2007 May; 68(1):159-65. PubMed ID: 17331666 [TBL] [Abstract][Full Text] [Related]
17. Five-year results: the initial clinical trial of MammoSite balloon brachytherapy for partial breast irradiation in early-stage breast cancer. Benitez PR; Keisch ME; Vicini F; Stolier A; Scroggins T; Walker A; White J; Hedberg P; Hebert M; Arthur D; Zannis V; Quiet C; Streeter O; Silverstein M Am J Surg; 2007 Oct; 194(4):456-62. PubMed ID: 17826055 [TBL] [Abstract][Full Text] [Related]
18. Novel use of the Contura for high dose rate cranial brachytherapy. Scanderbeg DJ; Alksne JF; Lawson JD; Murphy KT Med Dosim; 2011; 36(4):344-6. PubMed ID: 21144735 [TBL] [Abstract][Full Text] [Related]
20. Preliminary results and evaluation of MammoSite balloon brachytherapy for partial breast irradiation for pure ductal carcinoma in situ: a phase II clinical study. Benitez PR; Streeter O; Vicini F; Mehta V; Quiet C; Kuske R; Hayes MK; Arthur D; Kuerer H; Freedman G; Keisch M; Dipetrillo T; Khan D; Hudes R Am J Surg; 2006 Oct; 192(4):427-33. PubMed ID: 16978943 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]